Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Harbor Mid Cap Value Fund Josef Lakonishok, Menno Vermeulen, Puneet Mansharamani, Greg Sleight, Guy Lakonishok, Gal Skarishevsky | “We added to our position in Regeneron Pharmaceuticals, a biotech company in the Health Care sector. The stock ranks high on multiple cash flow and forecasted earnings measures — two of our most important measures of valuation. While the company pays a below-average dividend, Regeneron has been buying back stock, which we view positively. Price momentum over the past 12 months has been strong. In addition, several indicators of operating momentum also are attractive with improving operating margins and growth in sales. Overall, the stock ranks in the top 10% in our stock-ranking universe, which led to the second quarter purchase.” | NEUTRAL | Q2 2026 Aug 11, 2026 | View Pitch |
Longleaf Partners Fund Southeastern Asset Management, Inc. | “Healthcare company Regeneron was a detractor in the quarter after disappointing trial results for one of its pipeline drugs. When we first invested in the company last year, the keys to the case were continued strength at Dupixent, Eylea stabilization, pipeline success and intelligent capital allocation. Dupixent (over 50% of the value) has outgrown our expectations and Eylea (less than 15% of the value) has stabilized after some initial hiccups. There were three key pipeline readouts coming over the next 18 months when we invested, and Regeneron has now basically gone one out of three, when we thought two out of three was more likely. We trimmed some of our holding when the market was running hotter on Regeneron's pipeline prospects earlier this year. The market is now focused on that weaker near-term batting average and ignoring the company's strong long-term record. We have been encouraged to see the company lean into share repurchase when it has been most undervalued and continue to avoid large, value-destructive M&A.” | NEUTRAL | Q2 2026 Jul 13, 2026 | View Pitch |
Longleaf Partners Global Fund Ross Glotzbach | “Healthcare company Regeneron was a detractor in the quarter after disappointing trial results for one of its pipeline drugs. When we first invested in the company last year, the keys to the case were continued strength at Dupixent, Eylea stabilization, pipeline success and intelligent capital allocation. Dupixent (over 50% of the value) has outgrown our expectations and Eylea (less than 15% of the value) has stabilized after some initial hiccups. There were three key pipeline readouts coming over the next 18 months when we invested, and Regeneron has now basically gone one out of three, when we thought two out of three was more likely. We trimmed some of our holding when the market was running hotter on Regeneron's pipeline prospects earlier this year. The market is now focused on that weaker near-term batting average and ignoring the company's strong long-term record. We have been encouraged to see the company lean into share repurchase when it has been most undervalued and continue to avoid large, value-destructive M&A.” | NEUTRAL | Q2 2026 Jul 11, 2026 | View Pitch |
Longleaf Partners Fund Southeastern Asset Management, Inc. | “Regeneron – Healthcare company Regeneron was a detractor in the first half of the year but ended up as a contributor for the quarter and full year. It did not initially feel great, but our phased buy-in has worked well so far. We continue to like the company's strong position in allergic diseases (DUPIXENT) and oncology (LIBTAYO and others). We believe the market focuses too much on EYLEA, a retinal disease medication which is less than 20% of the company's value. The company has a net cash balance sheet and great owner-partners. Unlike most others in its industry, it has sworn off large M&A and was a material share repurchaser in 2025. We still are not paying much (or anything depending on how you do the math) for the company's sizeable pipeline value. After some initial pipeline disappointment in the first part of the year, there were more positives as the year went on. The P/V remains low, and we are excited for Regeneron to be a meaningful position entering the year. BSD Analysis: Regeneron is one of the few biopharma companies that consistently turns science into sustained cash flow. Its pipeline depth and discovery engine reduce dependence on any single product. Dupixent continues to expand indications, extending the growth runway. R&D productivity remains among the best in the industry, which justifies continued investment. Investors worry about eventual patent cliffs, but the pipeline keeps refilling. Regeneron operates more like a biotech factory than a lottery ticket. This is disciplined innovation at scale.” | BULL | Q4 2025 Jan 1, 2026 | View Pitch |
Longleaf Partners Fund Southeastern Asset Management, Inc. | “After a slow start to our holding period this year, Regeneron has found its footing and grown its value per share back to above where we started the year in our opinion. We still do not have to pay anything for multiple high quality pipeline candidates, and the company has become one of our larger share repurchasers with its net cash balance sheet. BSD Analysis: Core franchises (EYLEA/Dupixent economics) fund a robust pipeline, while net cash supports buybacks. As new indications mature, multi-year EPS growth visibility improves. On a premium but defensible multiple, upside rests on pipeline readouts and continued capital returns. Risks: biosimilar erosion and pricing.” | BULL | Q3 2025 Oct 1, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
